Accounting for Hypoglycemia Treatments in Continuous Glucose Metrics
Authors' conclusion
This new metric integrates HT behaviors into CGM-based analysis, offering a behavior-sensitive measure of hypoglycemia exposure for more robust T1D management. Our results show that HT can be seamlessly incorporated into existing CGM methods, enhancing treatment insights by accounting for HT variability.
Study context
- Population
- In-silico data and clinical continuous glucose monitoring (CGM) data with labeled hypoglycemia treatments (HTs), T1D
- Comparison
- HT-modified vs HT-unaware CGM-based hypoglycaemia metrics
- Outcome
- Reconstruction of avoided hypoglycemia exposure and HT detection
Methodological detailsin-silico data, clinical data with labeled HT
- In-silico data
- Clinical data with labeled HT
Main finding
As reported in the abstract
Reconstruction of avoided hypoglycemia exposure, correcting TBR with HT (in-silico), R2
.94
HT detector F1 score on clinical data with labeled HT
0.72
Further findings
Average number of HT per day in run-to-run application
TIR 70 to 180 mg/dL HT-modified system 84%
Original publication
Accounting for Hypoglycemia Treatments in Continuous Glucose Metrics. J Diabetes Sci Technol. Published 5 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →